ArticleNeurosurgical review2025
Descriptive epidemiology and prognostic factors of atypical teratoid/rhabdoid tumors in the United States, 2001-2021.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinicopathological Characterization of Pediatric Atypical Teratoid/Rhabdoid Tumors and an HE-IHC Dual-Path Deep Learning Model for Auxiliary Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- Pediatric Spinal Atypical Teratoid Rhabdoid Tumor: Recent Advances in Biology and Management Options.Cancers · 2026Review
- Aggressive atypical teratoid/rhabdoid tumor with extensive leptomeningeal metastasis in an 8-year-old boy: a case report and narrative review.Translational pediatrics · 2026Article
- Beyond Aqueductal Stenosis: A Case of an Atypical Teratoid/Rhabdoid Tumor Presenting With Neonatal Hydrocephalus.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical teratoid rhabdoid tumor (AT/RT) is a rare embryonal central nervous system tumor with a dismal prognosis that occurs mostly in early childhood. Since recent epidemiological and prognostic information is limited, we aimed to describe and analyze AT/RT-related incidences, temporal trends and prognostic factors. Incidence and survival data between 2001 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Descriptive epidemiology was utilized to assess incidences and rate ratios. Temporal trends were assessed by Joinpoint analysis. Prognostic factors were evaluated by survival analysis. A total of 393 patients were included in our analysis. Most patients developed tumors at less than 1 year of age (33.6%). The overall incidence was 0.084 per 100,000 population. According to the SEER 17 data, AT/RT represented 18.3% of all CNS malignant tumors diagnosed in infants aged < 1 year, with a relatively high incidence of 0.583. The overall incidence trend increased nonsignificantly from 2004 to 2021 (P = 0.572). Older age, more aggressive tumor resection, radiotherapy and chemotherapy administration, and nonmetastasis status were related to improved overall survival (OS) and cancer-specific survival (CSS) via Kaplan-Meier analysis. Multivariable Cox regression analysis indicated that age, extent of resection, radiotherapy, chemotherapy and metastasis status were independent prognostic factors for OS and CSS. AT/RT, particularly in infants under 1 year of age, should receive increased attention from epidemiologists and clinicians. An aggressive multimodal regimen including surgery combined with chemotherapy and radiotherapy is necessary.
Indexed as
Identifiers
39832059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.